TGFB1 and cancer: Notably, at the gene regulatory level, treatment of either Cmp14 or dBRD9-A, particularly Cmp14, led to significant suppression of several key pathways, including cancer progenitor signatures, stemness signatures, TGFB targets, SOX4 targets as well as early estrogen response, EMT and inflammatory response pathways in XVOA14590 PDX tumors (n=6) (Fig. 7D, Extended Data Fig. 7E-G).